Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

PARP inhibitor BS-201 plus chemotherapy: new option for triple-negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.07.09
Views: 22003
Rating:

Dr Joyce O'Shaughnessy - Baylor-Charles A. Sammons Cancer Center, US

Joyce O’Shaughnessy, MD, Baylor-Charles A. Sammons Cancer Center, Dallas, Texas, speaking at ASCO 2009: PARP Inhibitor BS-201 Plus Chemotherapy May Offer New Treatment Option for Triple-Negative Breast Cancer: A randomized Phase II study, featured in ASCO’s plenary session, shows that women with metastatic triple-negative breast cancer who received the investigational PARP inhibitor BSI-201, in combination with conventional chemotherapy, lived significantly longer and experienced significantly better progression-free survival than women who received standard chemotherapy alone.

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation